QIBA PET Amyloid Biomarker Committee
17 July 2015 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:	*Participants:*		**RSNA**
Co-chairs:	John Hoffman, MD	Nancy Obuchowski, PhD	Joe Koudelik
Satoshi Minoshima, MD, PhD	Abhinay Joshi, MS	Rathan Subramaniam, MD, PhD, MPH	Susan Weinmann
Eric Perlman, MD	Paul Kinahan, PhD, FIEEE	John Sunderland, PhD	
Anne Smith, PhD	Adriaan Lammertsma, PhD	Richard Wahl, MD, FACR	
	Lawrence MacDonald, PhD	Brian Zimmerman, PhD	

Administrative Update

- The changes in QIBA leadership were noted
    - QIBA Chair: Dr. Sullivan has stepped down and Dr. Jackson has filled this position
    - QIBA Vice-Chair: Dr. Perlman has succeeded Dr. Jackson

- NIBIB YR 4 project final reports due to RSNA by August 31 (no project extensions are possible)
    - PET Amyloid brain physical phantom (Dr Sunderland)
        - Gathering data and manual adjustment of 100s of phantom image sections ongoing
        - Drs Sunderland and Kinahan to discuss data-requirements offline
    - PET Amyloid brain DRO / phantom (Dr Kinahan)
        - DRO project on schedule and expected to complete by Aug 31
    - FDG-PET/CT Profile Feasibility Test - Part 2 (Dr Turkington)

- NIBIB YR 5 RFP
    - RSNA submitted a proposal on July 14
    - Funding decision expected late Aug/ early Sept 2015
    - Projects using contract funds for human subject imaging have been removed due to caveat in RFP language

- Project proposal scoring status
    - Generally, all NM proposals received favorable rankings by the QIBA Steering Cmte
    - Outcome pending NIBIB decision & available funding level

Profile Revision Work

- Claim language (Section 2)
    - Use partial literature dataset for initial performance estimates
    - Revise based on meta-analysis when available
    - Review 'dependencies / disclaimers'
    - Define performance requirement (e.g., repeatability coefficient or within subject standard deviation)
    - Consider different level of performance characteristics dependent upon absolute level of amyloid burden at baseline. To be investigated at time of literature review.
    - Define percent change as [(SUVR@time2 – SUVR@time1)/SUVR@time1 x 100 = %chg SUVR]
- Threshold(s) for tracer uptake time differential – to be discussed at future meeting
- BC members requested to review Profile draft of 16June2015 and submit suggested revisions, deletions, additions using the spreadsheet format previously provided to co-chairs and/or RSNA staff for compilation and future session review.

Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):

- **July 24:**   All NM BC Co-Chairs Call – note: in place of SPECT BC
- **July 31:**   SPECT Biomarker Ctte Call – note: switch from July 24
- **August 7:** FDG-PET Biomarker Ctte Call
- **August 14:** Amyloid Biomarker Ctte Call
- **August 21:** SPECT Biomarker Ctte Call
- **August 28:** Combined NM Biomarker Committees